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Atherosclerosis is an inﬂammatory disease of the vasculature regulated by cytokines. Macrophages play a
crucial role at all stages of this disease, including regulation of foam cell formation, the inﬂammatory
response and stability of atherosclerotic plaques. For example, matrix metalloproteinases produced by
macrophages play an important role in modulating plaque stability. More recently, the ADAMTS prote-
ases, which are known to play a key role in the control of cartilage degradation during arthritis, have been
found to be expressed in atherosclerotic lesions and suggested to have potentially important functions in
the control of plaque stability. Unfortunately, the action of cytokines on the expression of ADAMTS family
in macrophages is poorly understood. We have investigated the effect of classical cytokines (IFN-c and
TGF-b) and those that have been recently identiﬁed (TL1A and IL-17) on the expression of ADAMTS-1,
-4 and -5 in human macrophages. The expression of all three ADAMTS members was induced during dif-
ferentiation of monocytes into macrophages. TGF-b had a differential action with induction of ADAMTS-1
and -5 expression and attenuation in the levels of ADAMTS-4. In contrast, IFN-c suppressed the expres-
sion of ADAMTS-1 without having an effect on ADAMTS-4 and -5. Although TL-1A or IL-17A alone had
little effect on the expression of all the members, they induced their expression synergistically when
present together. These studies provide new insight into the regulation of key ADAMTS family members
in human macrophages by major cytokines in relation to atherosclerosis.
 2014 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction up modiﬁed low-density lipoproteins (LDL), particularly oxidizedAtherosclerosis is a progressive disease characterised by lipid
accumulation and inﬂammation within the walls of the large and
medium arteries [1]. The disease is initiated by the activation of
the arterial endothelium by a range of risk factors leading to inﬁl-
tration of immune cells, particularly T-lymphocytes and mono-
cytes [1]. The latter then differentiate into macrophages and takeLDL, to form lipid laden foam cells that characterise the fatty streak
seen in the early stages of the disease. As the disease progresses,
complex lesions develop that are usually covered with a ﬁbrous
cap composed of vascular smooth muscle cells (VSMCs) and extra-
cellular matrix (ECM) molecules. The ﬁbrous cap encloses a lipid-
rich necrotic core consisting of modiﬁed LDL, cholesterol and
apoptotic/necrotic cells. The acute symptoms of atherosclerosis
usually do not occur due to the plaque critically narrowing the ar-
tery but when an unstable plaque ruptures leading to a thrombotic
reaction [2]. The stability of a mature atherosclerotic plaque, which
is dictated by a balance between ECM synthesis and degradation, is
therefore very important in controlling acute events such as heart
attack and stroke [3].
ADAMTS proteases are a family of proteins that share a similar
domain pattern and substrate range; they are structurally related
to the matrix metalloproteinase (MMP) family and have been
implicated in a number of pathophysiological conditions including
osteoarthritis and, more recently, atherosclerosis [4–6]. The found-
ing member of the ADAMTS proteases was ﬁrst cloned, identiﬁed
and named in a study carried out in 1997 [7], from here the family
has grown to 19 members [4,5]. ADAMTS proteases are secreted
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pro-collagen, proteoglycans, hyalectans and cartilage oligomeric
matrix protein [4,8].
MMPs have been suggested to be major regulators of the ath-
erosclerotic process through re-modeling of the plaque ECM [9].
As the protein families are structurally related, the role for ADAM-
TS proteins in atherosclerosis could be similar to that of the MMPs
[4]. The central hypothesised role of the ADAMTS proteases within
the atherosclerotic plaque is cleavage of versican potentially lead-
ing to regulation of migration, proliferation, apoptosis and other
cellular events within VSMC and macrophages [4]. ADAMTS-1, -4,
-5 and -8 are expressed within human atherosclerotic plaques,
and macrophages have been identiﬁed as major contributors to-
wards ADAMTS expression in the disease [10–12]. ADAMTS prote-
ases are also expressed in VSMC and endothelial cells, but to a
lower extent than macrophages and foam cells [10,11]. ADAMTS-
1 expression has been studied in various mouse tissues and has
been shown to be at the highest level in the aorta [11]. In addition,
ADAMTS-4 mRNA is present in the aortas of the LDL receptor
(LDLR)/ apolipoprotein B (ApoB)100/100 mice before any athero-
sclerotic lesions are visible and the level of expression increased
as the lesions become more advanced [10]. In separate studies, ser-
um levels of ADAMTS-4 have also shown a signiﬁcant correlation
with the severity of coronary artery disease [13,14]. More recently,
ADAMTS-5 has been found to have a novel role in proteoglycan
turnover and lipoprotein retention in atherosclerosis [15]. These
ﬁndings, taken together, outline the potential regulatory role that
ADAMTS proteases could have over the stability of the atheroscle-
rotic plaque.
Despite the potentially important link between ADAMTS family
and atherosclerosis, limited in vitro studies have been carried out
on their regulation in macrophages by cytokines in relation to this
disease. The ﬁrst study investigated the expression and regulation
of ADAMTS proteases in macrophages, before and after differenti-
ation, by IFN-c, IL-1b and tumour necrosis factor (TNF)-a [10].
The expression of ADAMTS-4 and -8 was induced upon monocyte
to macrophage differentiation and macrophage expression of
ADAMTS-4, -7, -8 and -9 mRNA was further enhanced upon stim-
ulation with IFN-c or TNF-a. On the other hand, IFN-c attenuated
the expression of ADAMTS-1 [10]. The second study analysed the
effect of TGF-b stimulation on ADAMTS-4 expression in macro-
phages [16]. This anti-atherogenic cytokine inhibited the expres-
sion of ADAMTS-4 and small interfering RNA-mediated
knockdown revealed a critical role for Smads, p38 mitogen-acti-
vated protein kinase and c-Jun in this response [16]. These ﬁndings
together suggest potentially important roles for ADAMTS proteases
during atherosclerosis, demonstrate how regulation by speciﬁc
cytokines can inﬂuence their expression, and highlight the need
for further studies aimed to identifying the effect of different cyto-
kines implicated in this disease on the expression of ADAMTS fam-
ily members.
The objective of this study was therefore to investigate the ac-
tion of classical cytokines (TGF-b, IFN-c) and those that have been
more recently identiﬁed (TL1A and IL-17A) on the expression of
ADAMTS-1, -4 and -5 in human macrophages. In vivo studies in
mouse model systems have highlighted a pro-atherogenic role of
IFN-c [17,18] and an anti-atherogenic action of TGF-b [19]. The role
of TL1A, which interacts with death receptor 3 (DR3), in atheroscle-
rosis in vivo has not been investigated but in vitro studies indicate
that the cytokine promotes foam cell formation [20]. In addition, in
combination with IFN-c, the TL1A/DR3 axis has been shown to
have a role in atherosclerosis through stimulation of MMP-9,
potentially leading to de-stabilisation of the plaque [21]. IL-17A
has been regarded previously as pro-inﬂammatory as this cytokine
has been shown to induce many mediators such as TNF-a and IL-1
[22]. However, its role in the development of atherosclerosis in vivoremains controversial with both pro- and anti-atherogenic actions
being reported [23].
2. Materials and methods
2.1. Reagents
All chemicals were purchased from Sigma–Aldrich (Poole, UK)
unless otherwise stated. Recombinant human TGF-b, IFN-c, TL1A
and IL-17A were supplied by Peprotech (London, UK).
2.2. Cell culture
Most experiments were carried out in the human acute leukae-
mia cell line (THP-1) with key ﬁnding conﬁrmed in human mono-
cyte-derived macrophages (HMDM). The latter were obtained by
differentiation of monocytes isolated from buffy coats supplied
by the Welsh Blood service using Ficoll-Hypaque puriﬁcation de-
scribed elsewhere [24,25]. The cells were grown in complete
RPMI-1640 supplemented with 10% (v/v) heat-inactivated FCS
(56 C, 30 min), penicillin (100 U/ml), streptomycin (100 lg/ml)
and L-glutamine (2 mmol/L) at 37 C in a humidiﬁed atmosphere
containing 5% (v/v) CO2. THP-1 monocytes were differentiated into
macrophages using 160nM phorbol 12-myristate 13-acetate (PMA)
for 24 h. In all experiments, unless otherwise stated, macrophages
were incubated with TGF-b (30 ng/ml), IFN-c (1000U/ml), TL1A
(100 ng/ml), IL-17A (100 ng/ml) or TL1A and IL-17A for 24 h.
Recombinant human TGF-b, IFN-c, TL1A and IL-17A were reconsti-
tuted in PBS/0.1% BSA that was subsequently used as a vehicle
control.
2.3. Real-time quantitative PCR (RT-qPCR)
RNA extraction, reverse transcription and qPCR analysis were
performed as described elsewhere [24,25]. The sequences of oligo-
nucleotides, which were purchased from Sigma Aldrich (Poole, UK),
are shown in Supplementary Table I. Fold changes in expression
were calculated using 2(DCt1–DCt2), where DCt represents the dif-
ference between the threshold cycle (CT) for each target gene and
housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAP-
DH) mRNA transcript levels [25]. Melting curve analysis was per-
formed on each primer set to conﬁrm ampliﬁcation of a single
product and all amplicons were sequenced to ensure reaction spec-
iﬁcity (data not shown).
2.4. Western blotting
Total cell lysates were size-fractionated and analysed by wes-
tern blotting as previously described [24,25]. Samples were sub-
jected to electrophoresis alongside comparative molecular weight
markers (GE Healthcare, Wisconsin, USA) to determine the size of
the protein product. An antibody speciﬁc to ADAMTS-4 (PA1-
1749) was supplied by Thermo Fisher Scientiﬁc (Northumberland,
UK). Antibodies speciﬁc to apoE (0650-1904) and b-actin (A2228)
were supplied by Biogenesis (Poole, UK) and Sigma (Poole, UK)
respectively.
2.5. Statistical analysis
All data are presented as mean (±standard deviation (SD) on the
assigned number of independent experiments where, in experi-
ments involving HMDM, this refers to the number of independent
experiments performed using samples from different donors. Data
sets were tested for normality using the Shapiro–Wilk test.
Statistical analysis was carried out using either a Student’s t-test
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where homogeneity of variance was met; or Welch’s test of equal-
ity of means with Games–Howell post hoc analysis. Results were
regarded as signiﬁcant if P 6 0.05.Fig. 1. The expression of ADAMTS-1, -4 and -5 is induced during differentiation of
THP-1 monocytes into macrophages. THP-1 monocytes were treated with 160 nM
PMA for the indicated period of time and total cellular RNA was subjected to RT-
qPCR using primers against (A) apoE, (B) LPL, (C) ADAMTS-1, (D) ADAMTS-4 and (E)
ADAMTS-5. The mRNA expression levels were calculated using the comparative Ct
method and normalised to GAPDH mRNA levels with cells at 0 h given an arbitrary3. Results
3.1. Macrophage differentiation induced the expression of ADAMTS-1,
-4 and -5
It was of interest to investigate how the expression of ADAMTS-
1, -4 and -5 was regulated during monocyte-macrophage differen-
tiation. These experiments were carried out on the THP-1 cell line
which is widely utilised for such investigations as the responses in
them are conserved with primary macrophages and in vivo
conditions [24,26]. Indeed, this cell line has been used in previous
publications to study the regulation of ADAMTS expression in
human macrophages [10,16,27]. THP-1 monocytes are readily
differentiated into macrophages after stimulation with PMA
[26,27]. Previous studies have shown that the expression of
apolipoprotein E (apoE) and lipoprotein lipase (LPL) is increased
during PMA-induced differentiation of THP-1 monocytes into
macrophages [28,29] and they were therefore included as positive
controls. The expression of apoE and LPL mRNA was indeed
signiﬁcantly induced upon PMA-mediated differentiation of
THP-1 cells (Fig. 1, panels A and B). Similarly, ADAMTS-1, -4 and
-5 were expressed in THP-1 monocytes and their levels increased
signiﬁcantly during differentiation into macrophages (Fig. 1, panels
C–E). Although the expression of ADAMTS-5 failed to reach signif-
icance at 48 h and 72 h, the levels were higher than those seen in
monocytes.
The expression of ADAMTS-4 protein was also analysed by wes-
tern blot analysis. As shown in Fig. 2, the expression of ADAMTS-4
was signiﬁcantly increased after 24 and 48 h of PMA stimulation.
Although the levels of ADAMTS-4 at 72 h and 96 h did not reach
signiﬁcance, they were much higher than those in monocytes.
Overall, therefore, the induction of ADAMTS-1, -4 and -5
expression was signiﬁcant after 24 h of PMA stimulation in all
cases during RT-qPCR and, in the case of ADAMTS-4, by Western
blot analyses. For these reasons, all subsequent experiments that
investigated gene expression in THP-1 macrophages utilised a
24 h differentiation period with PMA.value of 1. Data represent the mean ± SD of 4 independent experiments for apoE
and LPL, and 7 independent experiments for ADAMTS-1, -4 and -5. Statistical
analysis was performed using one-way ANOVA (P < 0.05; P < 0.01; NS, not
signiﬁcant).3.2. TGF-b attenuated the expression of ADAMTS-4 and increased the
expression of ADAMTS-1 and -5 in human macrophages
TGF-b is highly expressed in atherosclerotic plaques and has
been implicated in several cellular changes during this disease
[19]. TGF-b predominantly shows anti-atherogenic properties,
highlighted by low serum levels being observed in patients with
advanced atherosclerosis and regions of the aorta with a high prob-
ability of lesion development displaying low levels of TGF-b
expression [19]. In addition, the inhibition of TGF-b activity and/
or expression in mouse models of atherosclerosis results in accel-
erated lesion development and an elevated inﬂammatory response
[19,25]. The action of TGF-b on the expression of ADAMTS-1, -4 and
-5 was therefore investigated. ApoE, whose expression is induced
by TGF-b, was included as a positive control.
Consistent with previous studies [30,31], the expression of
apoE mRNA and protein was induced by TGF-b (Fig. 3, panels
A and B). In addition, as expected [16], the cytokine attenuated
the expression of ADAMTS-4 mRNA (Fig. 3, panel D). In con-
trast, TGF-b induced the expression of ADAMTS-1 and -5 mRNA
(Fig. 3, panels C and E).3.3. IFN-c attenuated the expression of ADAMTS-1 and had no effect on
the expression of ADAMTS-4 and -5 in human macrophages
Studies in vitro have suggested a complex role for IFN-c with
both pro- and anti-atherogenic effects [17,18,32]. However, the
evidence from in vivo studies is clearer, and it has been demon-
strated that chronic administration of recombinant IFN-c en-
hanced atherosclerosis in apoE/ mice [17]. Also, within apoE/
and LDLR/ mice, genetic ablation of IFN-c, or the IFN-c receptors
reduced atherosclerosis [17]. The action of IFN-c on the expression
of ADAMTS-1, -4 and -5 was therefore investigated. ApoE, whose
expression is inhibited by IFN-c [33], was included as a positive
control.
As expected, the expression of apoE mRNA and protein was
attenuated by IFN-c (Fig. 4, panels A and B). Similarly, ADAMTS-1
mRNA expression was signiﬁcantly reduced by IFN-c stimulation
(Fig. 4, panel C). In contrast, IFN-c had no signiﬁcant effect on
Fig. 2. The expression of the ADAMTS-4 protein is induced during differentiation of
THP-1 monocytes into macrophages. THP-1 monocytes were treated with 160 nM
PMA for the indicated period of time and equal amount of total cellular protein was
subjected to Western blot analysis using antisera against ADAMTS-4 or b-actin as
indicated. Protein expression, as determined by densitometric analysis, was
normalised to b-actin and is displayed as a fold change compared to 0 h (arbitrarily
assigned as 1). Data represent the mean ± SD of three independent experiments.
Statistical analysis was performed using Student’s t test (P < 0.05; NS, not
signiﬁcant).
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The concentration of IFN-c used in these experiments was basedFig. 3. Differential action of TGF-b on the expression of ADAMTS-1, -4 and -5 in human
30 ng/ml TGF-b. (A, C, D, E), total cellular RNA was isolated and subjected to RT-qPCR usi
mRNA expression levels were calculated using the comparative Ct method and normali
arbitrary value of 1. Data represent the mean ± SD of 3 independent experiments for ap
total cellular protein were subjected to Western blot analysis using antisera against apoE
was normalised to b-actin and is displayed as a fold change compared to control (arbit
Statistical analysis was performed using Student’s t test (, P < 0.05; , P < 0.01; NS, noton previous studies investigating the effect of this cytokine in the
control of macrophage gene expression [32,34]. The results ob-
tained here differed slightly to another previously published study
that utilised 100 U/ml IFN-c [10]. In order to investigate whether
the differences were due to the concentration of the cytokine used,
a dose response experiment was carried out. The studies conﬁrmed
that ADAMTS-1 mRNA expression was reduced by IFN-c stimula-
tion; a signiﬁcant reduction in expression was observed after
250 U/ml, 500 U/ml and 1000 U/ml of the cytokine (Fig. 5, panel
A). On the other hand, ADAMTS-4 and -5 expression exhibited no
signiﬁcant change at all concentrations of IFN-c stimulation
(Fig. 5, panels B and C). In order to further conﬁrm that the results
obtained were not peculiar to the THP-1 cell line, representative
experiments were performed on primary HMDM. Similar to THP-
1 macrophages, IFN-c attenuated the expression of ADAMTS-1
and had no signiﬁcant effect on the expression of ADAMTS-4 and
-5 in HMDM (Fig. 6).
3.4. TL1A and IL-17A together, but not alone, induce the expression of
ADAMTS-1, -4 and -5 in human macrophages
As detailed above, both TL-1A and IL-17 have been shown to
have pro-atherogenic actions in vitro [20–22]. The action of TL1A
or IL-17A on the expression of ADAMTS-1, -4 and -5 was therefore
investigated. Consistent with previous studies [20], TL1A inhibited
the expression of apoE mRNA in THP-1 macrophages (Supplemen-
tary Fig. 1, panel A). In contrast, no signiﬁcant change was observedmacrophages. THP-1 macrophages were treated for 24 h with vehicle (Control) or
ng primers against (A) apoE, (C) ADAMTS-1, (D) ADAMTS-4 and (E) ADAMTS-5. The
sed to GAPDH mRNA levels with those from control, vehicle-treated cells given an
oE and 4 independent experiments for ADAMTS-1, -4 and -5. (B), equal amounts of
or b-actin as indicated. Protein expression as determined by densitometric analysis,
rarily assigned as 1). Data represent the mean ± SD of 3 independent experiments.
signiﬁcant).
Fig. 4. Differential action of IFN-c on the expression of ADAMTS-1, -4 and -5 in human macrophages. THP-1 macrophages were treated for 24 h with vehicle (Control) or
1000U/ml IFN-c. (A, C, D, E), total cellular RNA was isolated and subjected to RT-qPCR using primers against (A) apoE, (C) ADAMTS-1, (D) ADAMTS-4 and (E) ADAMTS-5. The
mRNA expression levels were calculated using the comparative Ct method and normalised to GAPDH mRNA levels with those in control, vehicle-treated cells given an
arbitrary value of 1. Data represent the mean ± SD of 3 independent experiments. (B), equal amount of total cellular protein was subjected to Western blot analysis using
antisera against apoE or b-actin as indicated. Protein expression as determined by densitometric analysis, was normalised to b-actin and is displayed as a fold change
compared to control (arbitrarily assigned as 1). Data represent the mean ± SD of 3 independent experiments. Statistical analysis was performed using Student’s t test
(P < 0.05; P < 0.01; NS, not signiﬁcant).
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panels B–D). Similarly, no signiﬁcant effect of IL-17A on the expres-
sion of ADAMTS-1, -4 and -5 were seen though, consistent with its
pro-atherogenic role in vitro, the cytokine inhibited apoE mRNA
expression (Supplementary Fig. 2). The concentration of
100 ng/ml of cytokine in these experiments was based on previous
research that investigated the TL1A- or IL-17A-mediated regulation
of gene expression [20,21,35]. In order to rule out the possibility
that the results were because of the concentration of TL1A or
IL-17A used, a dose response experiment was carried out. As
shown in Fig. 7, TL1A had no signiﬁcant effect on the expression
of ADAMTS-1 and -5 at all concentrations employed (panels A
and C). In addition, this cytokine had no signiﬁcant effect on
ADAMTS-4 expression at concentration of 25 ng/ml, 50 ng/ml and
100 ng/ml (Fig. 7, panel B). However, a statistically signiﬁcant
reduction of ADAMTS-4 expression was observed at the highest
concentration of TL1A used (200 ng/ml) (Fig. 7, panel B). For
IL-17A, there was no statistically signiﬁcant effect on the
expression of ADAMTS-1 and -4 (Fig. 7, panels D and E). Although,
IL-17A also had no signiﬁcant effect on ADAMTS-5 expression at
25 ng/ml, 50 ng/ml or 100 ng/ml, a statistically signiﬁcant
induction was seen at the highest concentration of 200 ng/ml
(Fig. 7, panel F).
IL-17A has been shown to induce the production of pro-inﬂam-
matory cytokines from human macrophages [36] and there is also
an increasing volume of literature suggesting that IL-17A can act
synergistically with cytokines such as TNF-a, IL-22 and IFN-c to
enhance pro-inﬂammatory responses [37–40]. Similarly, TL1A
has also been implicated in modulating pro-inﬂammatory re-
sponses from other cytokines: TL1A has been shown to synergisewith IL-12 and IL-18 to enhance the production of IFN-c from T-
cells and NK cells [41]. The synergy between the same agents
was also observed when TL1A augmented the IL-12/IL-18-induced
IFN-c production from CCR9+CD4+PB T-cells [42]. In addition, TL1A
has been shown to synergise with IFN-c to produce various pro-
inﬂammatory responses from THP-1 macrophages [21].
In the light of the ﬁndings detailed above, the effect of co-stim-
ulation of THP-1 macrophages and HMDM with TL1A and IL-17A
on the expression of ADAMTS-1, -4 and -5 was investigated. As
shown in Fig. 8, as expected, TL1A or IL-17A alone failed to signif-
icantly affect the expression of all three ADAMTS members in both
cellular systems. However, a statistically signiﬁcant induction of
ADAMTS-1, -4 and -5 expressions were seen when THP-1 macro-
phages and HMDMs were co-stimulated with the two cytokines
(Fig. 8). In contrast, TL1A or IL-17A did not affect the action of
IFN-c on ADAMTS-1, -4 and -5 expressions (Supplementary Fig. 3).4. Discussion
Recent studies have shown that ADAMTS proteases are ex-
pressed within the atherosclerotic plaque [4,12]. The action of
the proteases within the plaque could potentially lead to regula-
tion of plaque stability through various mechanisms [4]. Unfortu-
nately, the action of key cytokines implicated in the control of
inﬂammation during atherosclerosis on ADAMTS members is
poorly understood. The current investigations aimed to increase
understanding of how the expression of ADAMTS-1, -4 and -5 are
regulated by cytokines in human macrophages within the athero-
sclerotic plaque [1,43].
Fig. 6. The effect of IFN-c on the expression of ADAMTS-1, -4 and -5 in primary
HMDM. HMDM were treated for 24 h with vehicle (Control) or 1000 U/ml IFN-c.
Total cellular RNA was then isolated and subjected to RT-qPCR using primers
against (A) ADAMTS-1, (B) ADAMTS-4 and (C) ADAMTS-5. The mRNA expression
levels were calculated using the comparative Ct method and normalised to GAPDH
mRNA levels with those in control, vehicle-treated cells given an arbitrary value of
1. Data represent the mean ± SD of 3 independent experiments. Statistical analysis
was performed using Student’s t test (P < 0.05; NS, not signiﬁcant).
Fig. 5. The effect of different concentrations of IFN-c on the expression of ADAMTS-
1, -4 and -5 in THP-1 macrophages. THP-1 macrophages were treated for 24 h with
different concentrations of IFN-c as indicated. Total cellular RNA was then isolated
and subjected to RT-qPCR using primers against (A) ADAMTS-1, (B) ADAMTS-4 and
(C) ADAMTS-5. The mRNA expression levels were calculated using the comparative
Ct method and normalised to GAPDH mRNA levels with samples from cells treated
with 0 U/ml of cytokine given an arbitrary value of 1. Data represent the mean ± SD
of 3 independent experiments. Statistical analysis was performed using one-way
ANOVA (P < 0.05; P < 0.01; NS, not signiﬁcant).
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-4 and -5 were expressed in THP-1 macrophages and this was in-
creased signiﬁcantly during monocyte-macrophage differentiation
(Figs. 1 and 2). Previously, a study published in 2003 showed that
THP-1 monocytes expressed ADAMTS-4 and upon PMA stimula-
tion, the expression was signiﬁcantly increased [27]. The same
study also demonstrated that ADAMTS-4 expression was sup-
pressed by anti-atherogenic peroxisome proliferator-activated
receptor-c and retinoid X receptor agonists [27]. Another study
published in 2008 showed that ADAMTS-1, -4 and -5 were ex-
pressed in THP-1 monocytes [10]. In addition, after stimulation
of the cells with PMA for 24 h ADAMTS-4 expression increased
whereas that of ADAMTS-1 and -5 remained unchanged [10]. These
ﬁndings differ slightly to those obtained during our investigations.
A potential explanation for this inconsistency is that slightly differ-
ent protocols were used for differentiation of THP-1 cells between
the studies. Our study used a system that is employed by the
majority of the researchers in the ﬁeld and involves continuous
treatment with PMA. On the other hand, the previous study tried
to eliminate the direct effect of PMA on ADAMTS expression. They
used conditioned media from already differentiated THP-1 cells for
differentiation, or incubated the cells with PMA for 24 h and then
removed the PMA for 24 h before commencement of experiments
[10].
TGF-b has previously been shown to have a protective role dur-
ing atherosclerosis [19]. Studies on human and mouse plaques
have suggested a plaque-stabilising role for TGF-b, the cytokine
acts to lower pro-inﬂammatory cytokine production, reduceMMP actions and increase collagen synthesis [44–46]. The
attenuation of ADAMTS-4 expression by TGF-b is consistent with
an anti-atherogenic plaque-stabilising role for TGF-b within ath-
erosclerosis and backs up ﬁndings from a previous publication
[16]. However, the increased expression of ADAMTS-1 and -5 sug-
gest that these proteases have gene speciﬁc regulatory roles within
atherosclerotic plaques. The gene speciﬁc differences in expression
could also be down to the slight pleiotropic regulatory behaviour of
TGF-b during atherosclerosis [16,19].
IFN-cwas shown to attenuate ADAMTS-1 expression, but it had
no effect on the expression of ADAMTS-4 or -5 (Figs. 4–6). The dif-
ferences observed when comparing ﬁndings to a previous publica-
tion (i.e. induced expression of ADAMTS-4; decreased levels of
ADAMTS-1 and no effect on ADAMTS-5) [10] could be because of
a slightly different protocol for differentiation of THP-1 cells, as de-
tailed above. However, the differences cannot be because of the
concentration of IFN-c used as similar ﬁndings were obtained
when dose-response experiments were carried out (Fig. 5). The
previous study only used differentiated THP-1 cells to study the
regulation of ADAMTS expression by IFN-c [10] whereas we have
extended the analysis to HMDM (Fig. 6), where the potential off
target effects of PMA were eliminated, and the ﬁndings remained
the same as THP-1 macrophages. IFN-c has a pro-inﬂammatory
role within atherosclerosis and acts to de-stabilise the plaque via
increased MMP production and reduced collagen synthesis
[17,47,48]. The results obtained here are not fully consistent with
this pro-inﬂammatory role of IFN-c. Previously, ADAMTS-1 has
been hypothesised to accelerate plaque progression [11], yet the
Fig. 7. The effect of different concentrations of TL1A or IL-17 on the expression of ADAMTS-1, -4 and -5 in THP-1 macrophages. THP-1 macrophages were treated for 24 h with
different concentrations of (A–C) TL1A or (D–F) IL-17 as indicated. Total cellular RNA was then isolated and subjected to RT-qPCR using primers against (A and D) ADAMTS-1,
(B and E) ADAMTS-4 and (C and F) ADAMTS-5. The mRNA expression levels were calculated using comparative Ct method and normalised to GAPDH mRNA levels with
samples from cells treated with 0 ng/ml of the cytokine given an arbitrary value of 1. Data represent the mean ± SD of 3 independent experiments. Statistical analysis was
performed using one-way ANOVA (P < 0.05; NS, not signiﬁcant).
240 T.G. Ashlin et al. / Cytokine 64 (2013) 234–242expression in macrophages was reduced by IFN-c. The ﬁndings
potentially highlight the sometimes pleiotropic actions of IFN-c
during inﬂammation and atherosclerosis [17].
Members of the TNF receptor superfamily have previously been
implicated in the stimulation of MMP expression [21]. DR3 is the
receptor for TL1A and activation of this receptor has been impli-
cated in the induction of MMP-1, -9 and -13 from THP-1 cells in
the presence of IFN-c [21,49]. These ﬁndings, taken with the data
obtained in this investigation, indicate that DR3 and its ligand,
TL1A, have differential actions on different proteases that could
inﬂuence atherosclerotic plaque stability. TL1A has been shown
to have a weaker pro-atherogenic effect when acting on its own
whereas co-stimulation with IFN-c has been shown to increase
its pro-atherogenic actions [21]. However, this was not the case
with ADAMTS-1, -4 and -5 expression as the response obtained
when TL1A and IFN-c were together was similar to that seen with
IFN-c alone (Supplementary Fig. 3).
IL-17A and its roles during atherosclerosis are controversial
[50,51]. IL-17A is a relatively weak modulator of gene expression;
it could however work in combination with other cytokines to pro-
duce regulatory effects [52]. This could explain the variability in
some of the in vivo data that has been obtained during previous
studies [23,51–55]. Our studies show that IL-17A alone has no ef-
fect on the expression of ADAMTS-1, -4 or -5. We have of course
analysed the action of only IL-17A so other members, particularly
IL-17E and IL-17F, could play a role in regulating atherosclerotic
plaque stability as they activate a range of target receptors and sig-
nalling pathways and are present within atherosclerotic plaques
[56,57].A major novel ﬁnding from this study was that when TL1A and
IL-17A were added together, a synergistic response was observed
that resulted in the increased expression of ADAMTS-1, -4 and -5
in differentiated THP-1 cells and HMDM (Fig. 8). This is an impor-
tant observation because the understanding of how cytokines
interact during different disease processes is key in the detailed
delineation of the mechanistic actions of inﬂammatory mediators
[43]. The action of the ADAMTS proteases is largely associated with
pro-atherogenic endpoints [4]. In one previous study, ADAMTS-4
and -8 expression was shown to be up regulated in human athero-
sclerotic plaques and their expression from differentiated THP-1
cells was increased by stimulation with the pro-inﬂammatory
cytokine, TNF-a [10]. In addition, ADAMTS-4 expression was atten-
uated by stimulation with the anti-atherogenic cytokine TGF-b
[16]. Furthermore, the action of ADAMTS-7 during neointima for-
mation showed that VSMC migration was dependent on the prote-
ase [58]. The results on the action of TL1A and IL-17A are
consistent with the pro-inﬂammatory action of the proteases be-
cause both cytokines are largely considered pro-atherogenic
[21,54].5. Conclusion
We have demonstrated that the expression of ADAMTS-1,
-4 and -5 is induced during the differentiation of monocytes into
macrophages. The classical cytokines IFN-c and TGF-b have a
differential effect on the expression of these three members. On
the other hand, the more recently identiﬁed cytokines TL1A and
Fig. 8. TL1A and IL-17 together induce the expression of ADAMTS-1, -4 and -5 in THP-1 macrophages and primary HMDM. (A–C) THP-1 macrophages or (D–F) HMDM were
treated for 24 h with either vehicle (Control) or 100 ng/ml TL-1A and 100 ng/ml IL-17A alone or together, as indicated. Total cellular RNA was then isolated and subjected to
RT-qPCR using primers against (A and D) ADAMTS-1, (B and E) ADAMTS-4 and (C and F) ADAMTS-5. The mRNA expression levels were calculated using comparative Ct
method and normalised to GAPDH mRNA levels with samples from cells treated with vehicle given an arbitrary value of 1. Data represent the mean ± SD of 3 independent
experiments. Statistical analysis was performed using one-way ANOVA (P < 0.05; P < 0.01; P < 0.001; NS, not signiﬁcant).
T.G. Ashlin et al. / Cytokine 64 (2013) 234–242 241IL-17A alone have no effect on the expression of these three
members but induce their levels synergistically when present
together. The studies provide novel insight into the regulation of
these important proteases by key cytokines implicated in
atherosclerosis.
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